Abstract
Etanercept (ETN) is a fusion protein consisting of two chains of recombinant human TNF receptor fused with the Fc domain of human IgG. ETN is mainly bound on solubile TNFa and lymphotoxin, less on transmembrane form of TNFa.
Cell lysis or apoptosis of cells which express TNF.is not induced by ETN. Pharmacokinetic and pharmacodynamic properties of etanercept enable sc.administration of 50 mg 1x weekly.
The same dose is used for all indications, irrespective of the weight of the patient. Good efficacy and safety of etanercept in the treatment of rheumatoid arthritis, juvenile idiopathic ar-tritidy, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis was confirmed in RCTs and biologic registries.
Survival on etanercept treatment in these patients long and longer in comparison to other TNFi. No new safety signals during ETN therapy were observed during long-term treatment and TB risk is probably lower than with others TNF inhibitors.